In steroid-resistant nephrotic syndrome (SRNS), including focal segmental glomerulosclerosis (FSGS), genetic causes should be excluded at the time of renal biopsy. Pulse methylprednisolone should ...

Focal segmental glomerulosclerosis (FSGS) still lacks an FDA-approved therapy, but late-breaking post hoc results from the phase III DUPLEX trial -- presented at the National Kidney Foundation ...

Each year, millions of pulmonary nodules are identified incidentally or through lung cancer screening, and many involve biopsy to distinguish cancer from benign processes. Both navigational ...

To make the world smarter, happier, and richer. Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches ...

Pulmonary nodules are detected in more than 1.5 million U.S. residents every year. Nodules are identified incidentally on at least 20% of all diagnostic chest computed tomographic (CT) scans and ...

The review process for Focal Segmental Glomerulosclerosis (FSGS) was anticipated to be straightforward, but the requirement for a cardio-renal Advisory Committee (Adcom) meeting introduces a layer ...

Traditionally, punch biopsy sites have been sutured, but the benefit of this practice has never been scientifically demonstrated. In this prospective, randomized, method-comparison study ...

as well as TRPC6 inhibitor BI 764198 in phase 2 for rare kidney disease focal segmental glomerulosclerosis (FSGS). In oncology, she highlighted MDM2-p53 antagonist brigimadlin, which has advanced ...

Instrument 2015/541 provides relief from the obligation to distribute FSGs when general advice is presented within expert reports that form part of another party’s disclosure document.

thorax.dk Background: A study was undertaken to evaluate the clinical impact of endoscopic ultrasound guided fine needle aspiration biopsy (EUS-FNA) in patients with mediastinal masses suspected of ...

19 May 2025 Adopting a platform approach to designing new therapies will speed the delivery of innovative genomic treatments to patients—but only if developers, regulators, and manufacturers work ...